BIOMAT Database Logo BIOMAT Database Logo

Immune responses of infants vaccinated with serotype 6B pneumococcal polysaccharide conjugated with tetanus toxoid. 1997

S T Sigurdardottir, and G Vidarsson, and T Gudnason, and S Kjartansson, and K G Kristinsson, and S Jonsson, and H Valdimarsson, and G Schiffman, and R Schneerson, and I Jonsdottir
Department of Immunology, National University Hospital, Reykjavik, Iceland.

BACKGROUND Streptococcus pneumoniae is a major cause of meningitis, bacteremia, pneumonia and otitis media. Pneumococcal polysaccharides are not immunogenic in infants, but improved immunogenicity of polysaccharide-protein conjugates has been demonstrated. Antibiotic-resistant pneumococci have increased the need for an effective vaccine. OBJECTIVE To study the safety and immunogenicity of a pneumococcal type 6B polysaccharidetetanus toxoid conjugate (Pn6B-TT) in infants and to assess the function of antibodies. METHODS Healthy infants were injected, Group A at 3, 4 and 6 months (n = 21) and Group B at 7 and 9 months (n = 19). Booster injection was given at 18 months. Antibodies were measured by enzyme-linked immunosorbent assay and radioimmunoassay, and functional activity was measured by opsonization of radiolabeled pneumococci. Nasopharyngeal cultures were obtained. RESULTS No significant adverse reactions were observed. Pn6B-IgG (enzyme-linked immunosorbent assay) increased to a geometric mean of 0.62 microgram/ml (P = 0.367, compared with prevaccination titers) in Group A at 7 months and 1.22 micrograms/ml (P < 0.001) in Group B at 10 months. Total Pn6B antibodies (radioimmunoassay) were 44 ng of antibody N/ml (P < 0.053) in Group A and 211 ng of antibody N/ml (P < 0.001) in Group B. A smaller increase in IgM and IgA anti-Pn6B was observed. Reinjection at 18 months elicited booster responses in total and IgG anti-Pn6B; 62% of those in Group A and 79% of those in Group B had > 300 ng of antibody N/ml. Opsonic activity, after initial and booster vaccinations, correlated with Pn6B-antibody titers. Three infants with nasopharyngeal cultures repeatedly positive for serogroup 6 had poor serum IgG responses. CONCLUSIONS Our results demonstrate that Pn6B-TT is safe, elicits functional antibodies and memory responses in infants.

UI MeSH Term Description Entries
D007071 Immunoglobulin A, Secretory The principle immunoglobulin in exocrine secretions such as milk, respiratory and intestinal mucin, saliva and tears. The complete molecule (around 400 kD) is composed of two four-chain units of IMMUNOGLOBULIN A, one SECRETORY COMPONENT and one J chain (IMMUNOGLOBULIN J-CHAINS). Colostral IgA,IgA, Exocrine,IgA, Secretory,SIgA,Secretory IgA,Secretory Immunoglobulin A,Exocrine IgA,IgA, Colostral
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D009305 Nasopharynx The top portion of the pharynx situated posterior to the nose and superior to the SOFT PALATE. The nasopharynx is the posterior extension of the nasal cavities and has a respiratory function. Rhinopharynx,Choanae,Nasopharynges,Nasopharynxes,Rhinopharynges,Rhinopharynxes
D010587 Phagocytosis The engulfing and degradation of microorganisms; other cells that are dead, dying, or pathogenic; and foreign particles by phagocytic cells (PHAGOCYTES). Phagocytoses
D011135 Polysaccharides, Bacterial Polysaccharides found in bacteria and in capsules thereof. Bacterial Polysaccharides
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000907 Antibodies, Bacterial Immunoglobulins produced in a response to BACTERIAL ANTIGENS. Bacterial Antibodies
D012463 Saliva The clear, viscous fluid secreted by the SALIVARY GLANDS and mucous glands of the mouth. It contains MUCINS, water, organic salts, and ptylin. Salivas

Related Publications

S T Sigurdardottir, and G Vidarsson, and T Gudnason, and S Kjartansson, and K G Kristinsson, and S Jonsson, and H Valdimarsson, and G Schiffman, and R Schneerson, and I Jonsdottir
Immune responses of young mice to pneumococcal type 9V polysaccharide-tetanus toxoid conjugate.
July 1994, Infection and immunity,
S T Sigurdardottir, and G Vidarsson, and T Gudnason, and S Kjartansson, and K G Kristinsson, and S Jonsson, and H Valdimarsson, and G Schiffman, and R Schneerson, and I Jonsdottir
Identification of glycosylated regions in pneumococcal PspA conjugated to serotype 6B capsular polysaccharide.
April 2014, Glycoconjugate journal,
S T Sigurdardottir, and G Vidarsson, and T Gudnason, and S Kjartansson, and K G Kristinsson, and S Jonsson, and H Valdimarsson, and G Schiffman, and R Schneerson, and I Jonsdottir
Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens.
November 1997, The Pediatric infectious disease journal,
S T Sigurdardottir, and G Vidarsson, and T Gudnason, and S Kjartansson, and K G Kristinsson, and S Jonsson, and H Valdimarsson, and G Schiffman, and R Schneerson, and I Jonsdottir
Salmonella typhi O-polysaccharide--tetanus toxoid conjugated vaccine.
August 1994, Vaccine,
S T Sigurdardottir, and G Vidarsson, and T Gudnason, and S Kjartansson, and K G Kristinsson, and S Jonsson, and H Valdimarsson, and G Schiffman, and R Schneerson, and I Jonsdottir
Serotype 6B pneumococcal meningitis in an immunocompetent infant immunized with heptavalent pneumococcal conjugated vaccine.
February 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
S T Sigurdardottir, and G Vidarsson, and T Gudnason, and S Kjartansson, and K G Kristinsson, and S Jonsson, and H Valdimarsson, and G Schiffman, and R Schneerson, and I Jonsdottir
Dose dependency of antibody response in infants and children to pneumococcal polysaccharides conjugated to tetanus toxoid.
June 1999, Vaccine,
S T Sigurdardottir, and G Vidarsson, and T Gudnason, and S Kjartansson, and K G Kristinsson, and S Jonsson, and H Valdimarsson, and G Schiffman, and R Schneerson, and I Jonsdottir
Antibody response to Haemophilus influenzae type b capsular polysaccharide conjugated to tetanus toxoid in preterm infants.
June 1996, The Pediatric infectious disease journal,
S T Sigurdardottir, and G Vidarsson, and T Gudnason, and S Kjartansson, and K G Kristinsson, and S Jonsson, and H Valdimarsson, and G Schiffman, and R Schneerson, and I Jonsdottir
Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid.
November 1997, The Pediatric infectious disease journal,
S T Sigurdardottir, and G Vidarsson, and T Gudnason, and S Kjartansson, and K G Kristinsson, and S Jonsson, and H Valdimarsson, and G Schiffman, and R Schneerson, and I Jonsdottir
Immunogenicity of Streptococcus pneumoniae type 6B and 14 polysaccharide-tetanus toxoid conjugates and the effect of uncoupled polysaccharide on the antigen-specific immune response.
December 1998, Vaccine,
S T Sigurdardottir, and G Vidarsson, and T Gudnason, and S Kjartansson, and K G Kristinsson, and S Jonsson, and H Valdimarsson, and G Schiffman, and R Schneerson, and I Jonsdottir
Human T lymphotropic virus type II infection and humoral responses to pneumococcal polysaccharide and tetanus toxoid vaccines.
April 2005, The Journal of infectious diseases,
Copied contents to your clipboard!